Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturised antibodies, opening the way for a potential new class of treatments for diseases.
Worldwide, otherwise healthy adolescents and young people without underlying conditions are sometimes severely affected by COVID-19, with the viral infection in the worst cases quickly becoming life-threatening. But why is this happening?
Seasonal colds are by all accounts no fun, but new research suggests the colds you've had in the past may provide some protection from COVID-19.
New study addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular structure and sequence of the SARS-CoV-2 spike protein could be behind life-threatening inflammatory conditions MIS-C and cytokine storm.
In a new study, researchers at La Jolla Institute for Immunology (LJI) report that a protein called TL1A drives fibrosis in several mouse models, triggering tissue remodeling, and making it harder for lungs and airways to function normally.
Two new studies offer an explanation for why COVID-19 cases can be so variable. A subset of patients has mutations in key immunity genes; other patients have auto-antibodies that target the same components of the immune system. Both circumstances could contribute to severe forms of the disease.
Individuals with severe forms of COVID-19 disease can present with compromised type I interferon (IFN) responses based on their genetics, according to results published in two papers today in the journal Science. Type I IFN responses are critical for protecting cells and the body from more severe disease after acute viral infection.
The National Cancer Institute award provides extended support for researchers to pursue projects with groundbreaking cancer research potential
Mesothelioma is a deadly cancer mainly caused by exposure to asbestos fibers.
Gary Corbin, 63, dropped a heavy hurricane window shutter, which gashed his leg before it hit the ground. After wintering in Florida, this resident of Grosse Pointe Farms had been helping his significant other close down her Palm Beach Gardens home before they returned to Michigan in mid-June. He treated the wound and kept it covered on the drive north.
In this research, the investigators studied the effect of TDF/FTC in patients who were using the drug to prevent HIV, and in the absence of active HIV infection. The researchers observed patients over the past five years and also included data from two earlier studies.
Achieving herd immunity to COVID-19 is an impractical public health strategy, according to a new model developed by University of Georgia scientists. The study recently appeared in Proceedings of the National Academy of Sciences.
The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults. The findings also have important implications for vaccines and drugs being developed to curb COVID-19. The study was published today in Science Translational Medicine and was conducted by scientists at Albert Einstein College of Medicine, Children’s Hospital at Montefiore (CHAM), and Yale University.
Free virtual event October 2-3 connecting cancer patients and caregivers with leading immunotherapy experts and patient advocates treated with immunotherapy
Airway cell analyses showing an activated immune axis could pinpoint the COVID-19 patients who will most benefit from targeted therapies
A new study conducted by researchers at Rambam Medical Center and the Technion reveals surprising findings, namely that cancer patients may not be associated with the broad range of at-risk groups of people suffering from morbidities.
A multi-layered, virus-specific immune response is important for controlling SARS-CoV-2 during the acute phase of the infection and reducing COVID-19 disease severity, with the bulk of the evidence pointing to a much bigger role for T cells than antibodies.
Why do some people have severe reactions to COVID whereas others do not? Are there overlooked or unexplained factors in how people respond to the COVID virus connected to their gut microbiome? Could microbiome predict the severity of illness among those exposed to the virus?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition. It is especially important now when multiple vaccines against COVID-19 are being developed.
Researchers at Washington University School of Medicine in St. Louis have discovered that a molecule produced by the immune system acts on the brain to change the behavior of mice.
This year, as COVID-19 continues to spread, it’s more important than ever that anyone with asthma get a flu shot to keep them healthy and out of the hospital.
Researchers created a system that uses CRISPR in a new way. Rather than acting on the genome to create permanent change, their system briefly suppresses genes specific to adenovirus antibody production, just long enough for the virus to deliver its gene therapy cargo unimpeded.
In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the likelihood of becoming infected with the coronavirus. The findings were published Sept. 3 in JAMA Network Open.
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society’s journal, Endocrinology.
New findings show that some patients with a rare and aggressive form of leukodystrophy may benefit from receiving treatment with a class of targeted therapy drugs that could improve their neurological function.
Why so many COVID-19 patients get blood clots (thrombosis) remains uncertain.
UC San Diego Health will be part of the Phase III national AstraZeneca clinical trial that will recruit up to 30,000 participants at multiple sites across the country to assess the safety and efficacy of a vaccine to prevent COVID-19.
The team from Marien Hospital and the department of Virology of Ruhr-Universität Bochum (RUB) as well as the Clinic for Infectious Diseases, the Clinic of Anesthesiology and the Institute for Virology of University Medicine Essen studied specific antibodies and T cells occurring in recovered, seriously ill and deceased Covid-19 patients.
Johns Hopkins Medicine researchers have added to evidence that a gene responsible for turning off a cell’s natural “suicide” signals may also be the culprit in making breast cancer and melanoma cells resistant to therapies that use the immune system to fight cancer. A summary of the research, conducted with mice and human cells, appeared Aug. 25 in Cell Reports.
As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.
New research is shedding light on the development of the brain’s immune defenses – and how those defenses respond to strokes that strike one in 4,000 babies in the first month of life.
Panelists will discuss topics such as the announcement of FDA approval for convalescent plasma, production and deployment of a vaccine, and the latest in treatment protocols and survival rates.
In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.
Prof. Ido Amit and his team’s INs-seq technology allows them to see inside tens of thousands of individual cells, at once, in unprecedented detail. The group has already used the method to identify a new subset of cancer-supporting immune cells that, when blocked in mice, boosted the anti-tumor immune response and killed the cancer.
Blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes.
Scientists are examining how specialized immune cells called macrophages recognize and destroy target cells and why they sometimes do not.
Researchers at UC San Diego School of Medicine report that the lasting nature of inflammatory bowel disease may be due to a type of long-lived immune cell that can provoke persistent, damaging inflammation in the intestinal tract.
Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.
DALLAS – Aug. 24, 2020 – The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule. Now, UT Southwestern scientists have revealed that STING also activates a separate pathway, one that directly kills tumor-fighting immune cells. Among other implications, the finding could lead to development of longer-lasting immunotherapies to fight cancer.
In the most comprehensive study of COVID-19 pediatric patients to date, Massachusetts General Hospital (MGH) and Mass General Hospital for Children (MGHfC) researchers provide critical data showing that children play a larger role in the community spread of COVID-19 than previously thought.
Researchers in Spain have identified a non-coding RNA molecule that helps lung cancer cells proliferate and avoid being killed by the body’s immune cells. The study, which will be published August 27 in the Journal of Cell Biology (JCB), suggests that targeting this RNA molecule could boost the effectiveness of immunotherapies that are currently only successful in ~20% of lung cancer patients.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body’s immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
Watch live and recorded press conferences at https://www.acs.org/content/acs/en/pressroom/news-room/press-conferences.html. Press conferences will be held Monday, Aug. 17 through Thursday, Aug. 20, 2020
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right